These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 10604326)

  • 1. Longitudinal changes in peak urinary flow rates in a community based cohort.
    Roberts RO; Jacobsen SJ; Jacobson DJ; Rhodes T; Girman CJ; Lieber MM
    J Urol; 2000 Jan; 163(1):107-13. PubMed ID: 10604326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostatic central zone volume, lower urinary tract symptom severity and peak urinary flow rates in community dwelling men.
    Corica FA; Jacobsen SJ; King BF; Bostwick DG; Jacobson DJ; Girman CJ; Lieber MM
    J Urol; 1999 Mar; 161(3):831-4. PubMed ID: 10022695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment for benign prostatic hyperplasia among community dwelling men: the Olmsted County study of urinary symptoms and health status.
    Jacobsen SJ; Jacobson DJ; Girman CJ; Roberts RO; Rhodes T; Guess HA; Lieber MM
    J Urol; 1999 Oct; 162(4):1301-6. PubMed ID: 10492184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diabetes and benign prostatic hyperplasia progression in Olmsted County, Minnesota.
    Burke JP; Jacobson DJ; McGree ME; Roberts RO; Girman CJ; Lieber MM; Jacobsen SJ
    Urology; 2006 Jan; 67(1):22-5. PubMed ID: 16413325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tracking of longitudinal changes in measures of benign prostatic hyperplasia in a population based cohort.
    St Sauver JL; Jacobson DJ; Girman CJ; Lieber MM; McGree ME; Jacobsen SJ
    J Urol; 2006 Mar; 175(3 Pt 1):1018-22; discussion 1022. PubMed ID: 16469608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlations between longitudinal changes in transitional zone volume and measures of benign prostatic hyperplasia in a population-based cohort.
    St Sauver JL; Jacobson DJ; Girman CJ; McGree ME; Lieber MM; Jacobsen SJ
    Eur Urol; 2006 Jul; 50(1):105-11. PubMed ID: 16466847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study.
    Kok ET; Schouten BW; Bohnen AM; Groeneveld FP; Thomas S; Bosch JL
    J Urol; 2009 Feb; 181(2):710-6. PubMed ID: 19091352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of anthropometric measures with the presence and progression of benign prostatic hyperplasia.
    Burke JP; Rhodes T; Jacobson DJ; McGree ME; Roberts RO; Girman CJ; Lieber MM; Jacobsen SJ
    Am J Epidemiol; 2006 Jul; 164(1):41-6. PubMed ID: 16611664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of dutasteride on the peripheral and transition zones of the prostate and the value of the transition zone index in predicting treatment response.
    Marks LS; Roehrborn CG; Wolford E; Wilson TH
    J Urol; 2007 Apr; 177(4):1408-13. PubMed ID: 17382742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence rates and risk factors for acute urinary retention: the health professionals followup study.
    Meigs JB; Barry MJ; Giovannucci E; Rimm EB; Stampfer MJ; Kawachi I
    J Urol; 1999 Aug; 162(2):376-82. PubMed ID: 10411042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal prostate growth rates during 5 years in randomly selected community men 40 to 79 years old.
    Rhodes T; Girman CJ; Jacobsen SJ; Roberts RO; Guess HA; Lieber MM
    J Urol; 1999 Apr; 161(4):1174-9. PubMed ID: 10081864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Morrill B; Montorsi F;
    J Urol; 2008 Feb; 179(2):616-21; discussion 621. PubMed ID: 18082216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between urinary flow rate, voided volume, and patient age in a community-based population.
    Oesterling JE; Girman CJ; Panser LA; Chute CG; Barrett DM; Guess HA; Lieber MM
    Prog Clin Biol Res; 1994; 386():125-39. PubMed ID: 7528382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between prostatic urethral angle and urinary flow rate: its implication in benign prostatic hyperplasia pathogenesis.
    Cho KS; Kim JH; Kim DJ; Choi YD; Kim JH; Hong SJ
    Urology; 2008 May; 71(5):858-62. PubMed ID: 18343484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The natural history of benign prostatic hyperplasia.
    Fitzpatrick JM
    BJU Int; 2006 Apr; 97 Suppl 2():3-6; discussion 21-2. PubMed ID: 16507045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphisms in the 5alpha reductase type 2 gene and urologic measures of BPH.
    Roberts RO; Bergstralh EJ; Farmer SA; Jacobson DJ; McGree ME; Hebbring SJ; Cunningham JM; Anderson SA; Thibodeau SN; Lieber MM; Jacobsen SJ
    Prostate; 2005 Mar; 62(4):380-7. PubMed ID: 15389785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective association between nonsteroidal antiinflammatory drug use and measures of benign prostatic hyperplasia.
    St Sauver JL; Jacobson DJ; McGree ME; Lieber MM; Jacobsen SJ
    Am J Epidemiol; 2006 Oct; 164(8):760-8. PubMed ID: 16905643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New diagnostic and treatment guidelines for benign prostatic hyperplasia. Potential impact in the United States.
    Jacobsen SJ; Girman CJ; Guess HA; Oesterling JE; Lieber MM
    Arch Intern Med; 1995 Mar; 155(5):477-81. PubMed ID: 7532392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dutasteride improves objective and subjective disease measures in men with benign prostatic hyperplasia and modest or severe prostate enlargement.
    Gittelman M; Ramsdell J; Young J; McNicholas T
    J Urol; 2006 Sep; 176(3):1045-50; discussion 1050. PubMed ID: 16890688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia.
    Kaplan SA; Walmsley K; Te AE
    J Urol; 2005 Dec; 174(6):2273-5. discussion 2275-6. PubMed ID: 16280803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.